On 04 Nov 2019, Halozyme Therapeutics, Inc. (NASDAQ: HALO) remained amongst the day losers and traded with modification of -0.68% on volume of 8,171,927 shares in the last session as compared to average volume of 706301 shares. During last trade its minimum cost was $14.61 and it gained greatest cost of $16.17.
Based on the absence of benefit over standard-of-care in this research study, which carried out well versus published information, we will be stopping PEGPH20 scientific advancement,” mentioned Dr. Helen Torley, president and CEO of Halozyme. I would like to extend a heartfelt thank you to all those who supported and who made this research study possible, consisting of the patients who were enrolled, their households, our investigators, their personnel, our investors and all of the devoted Halozyme employees.”
HALO has a gross margin of 93.00% and an operating margin of -20.10% while its earnings margin stayed -23.50% for the last 12 months. The rate moved ahead of -0.25% from the mean of 20 days, -2.26% from mean of 50 days SMA and performed -4.84% from mean of 200 days cost.
Halozyme Therapeutics, Inc. (HALO) just recently reported that the HALO-301 Phase 3 scientific research study examining investigational new drug PEGPH20 as a first-line treatment for treatment of patients with metastatic pancreas cancer failed to reach the primary endpoint of general survival.